ArticleAnnals of medicine2025
Endoscopic resection for gastric subepithelial tumours: a retrospective cohort study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough endoscopic resection (ER) is an established technique for gastric subepithelial tumours (SETs), comprehensive data on its efficacy and safety remain limited. This study aimed to evaluate the efficacy and safety of ER in patients with gastric SETs and to identify risk factors associated with procedure-related complications. MATERIALS AND
methodsThis retrospective study included 483 patients who underwent ER for gastric SETs between February 2012 and May 2023. Patient demographics, tumour characteristics, and clinical outcomes were evaluated. Multivariate analysis was performed to identify risk factors for complications.
resultsThe median tumour size was 1.2 cm (range: 0.5-6.0 cm). The complete resection rate was 93.8%. Complications occurred in 6.8% of cases, including perioperative bleeding (2.1%), perforation (1.7%), and both (0.4%), with 0.8% of cases requiring conversion to surgery. Larger tumours notably increased the risks of incomplete resection (odds ratio [OR] = 1.605, 95% confidence interval [CI]: 1.066-2.416,
conclusionsER is an effective and generally safe treatment modality for managing gastric SETs. However, larger tumour size and irregular shape are significant risk factors for adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.